Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Aug 1;108(8):2249-2254.
doi: 10.3324/haematol.2022.282269.

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study

Binod Dhakal  1 , Mei-Jei Zhang  2 , Linda J Burns  3 , Xiaoying Tang  3 , Christa Meyer  4 , Lih-Wen Mau  4 , Ajay K Nooka  5 , Edward Stadtmauer  6 , Ivana N Micallef  7 , Joseph McGuirk  8 , Luciano Costa  9 , Mark B Juckett  10 , Nina Shah  11 , Richard E Champlin  12 , Saad Z Usmani  13 , Sherif S Farag  14 , Taiga Nishihori  15 , Vivek Roy  16 , Andrew Bodiford  17 , Yvonne J Barnes  18 , Edward J Drea  19 , Parameswaran Hari  3 , Mehdi Hamadani  20
Affiliations
Observational Study

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study

Binod Dhakal et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Costs by mobilization strategy. (A) Median total costs by time period and mobilization strategy in the health economics set. Note that the median total costs varied by mobilization strategy in the pre-apheresis period (P<0.0001). Total costs include inpatient, outpatient, home healthcare, and outpatient pharmacy costs. (B) Median percent of total costs by payment type and mobilization strategy. Note that both Medicare payment and “patient responsibility” varied by mobilization strategy (both P<0.0001). Patient responsibility included co-payment, co-insurance, and deductibles. The number of patients with a secondary payer was less than 11 (not reported). Total costs include inpatient, outpatient, home healthcare, and outpatient pharmacy costs. G-CSF: granulocyte colony-stimulating factor.
See this image and copyright information in PMC

References

    1. Attal M, Lauwers-Cances V, Hulin C, et al. . Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. - PMC - PubMed
    1. Gay F, Musto P, Rota-Scalabrini D, et al. . Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705-1720 - PubMed
    1. Wood WA, Whitley J, Moore D, et al. . Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy. Biol Blood Marrow Transplant. 2011;17(1):141-146. - PubMed
    1. Dhakal B, Veltri LW, Fenske TS, et al. . Hematopoietic progenitor cell mobilization with ifosfamide, carboplatin, and etoposide chemotherapy versus plerixafor-based strategies in patients with Hodgkin and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22(10):1773-1780. - PubMed
    1. DiPersio JF, Stadtmauer EA, Nademanee A, et al. . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. - PubMed

Publication types

Substances